Rubio Angel J, Zhong Xuemei, Porter Tyrone M
Department of Pharmacology and Experimental Therapeutics, Boston University, Boston, MA, USA.
Hematology and Medical Oncology Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Cogent Biol. 2019;5(1). doi: 10.1080/23312025.2019.1662931. Epub 2019 Sep 11.
The recent emergence of immunotherapies is transforming cancer treatments. Although many cancer immunotherapies are finding enormous success for treating hematologic tumors, a major obstacle for the treatment of solid tumors is localizing immune cells to the tumor site. Therefore, we have developed a technology that is capable of directing immune cell migration. Specifically, we have packaged chemokines, signaling molecules that promote immune cell migration, inside polyethylene glycol decorated-liposomes. The release profiles of chemokines and other large molecules from the liposomes have been examined in serum-containing media. We have demonstrated that the liposomes are able to release chemokines to induce immune cell migration. Additionally, these liposomes have been shown in vitro to limit cancer cell growth through increased immune cell recruitment. This strategy of encapsulating chemokines within liposomes paves the way for additional cancer immunotherapies and chemokine-based therapies.
免疫疗法的近期出现正在改变癌症治疗方式。尽管许多癌症免疫疗法在治疗血液肿瘤方面取得了巨大成功,但治疗实体瘤的一个主要障碍是将免疫细胞定位到肿瘤部位。因此,我们开发了一种能够引导免疫细胞迁移的技术。具体而言,我们已将趋化因子(促进免疫细胞迁移的信号分子)包装在聚乙二醇修饰的脂质体内。已在含血清培养基中检测了趋化因子和其他大分子从脂质体中的释放情况。我们已经证明脂质体能够释放趋化因子以诱导免疫细胞迁移。此外,这些脂质体在体外已显示通过增加免疫细胞募集来限制癌细胞生长。将趋化因子包裹在脂质体内的这种策略为更多癌症免疫疗法和基于趋化因子的疗法铺平了道路。